About EV-077


EV-077 is in development as a potential pharmaceutical for the treatment of  diabetic nephropathy and other diabetic complications. It is in Phase II clinical studies.

In 2013, Evolva out-licensed EV-077 to Serodus (Oslo, Norway). Serodus aims to bring EV-077 through Phase II and then decide whether or not to partner for the final clinical trials and commercialisation. Evolva is entitled to clinical and regulatory milestones as well as a single-digit royalty on sales. If Serodus sublicenses EV-077 then Evolva will receive up to 30% of Serodus’ total licensing income.

As of Q2 2015 Serodus continues active development of EV-077.

  • right first  image

    EV-077 is a more potent inhibitor of platelet function than aspirin

    EV-077 is one of our legacy pharma programs. In this study the platelet function of EV-077 is compare to aspirin. Out-licensed to Norway's Serodus ASA, EV-077 is being developed for diabetic nephropathy, a progressive kidney disease stemming from diabetes.

    Journal of Thrombosis & Haemostasis
  • right first  image

    Resveratrol’s effect on glucose control and insulin sensitivity. A meta-analysis.

    A meta analysis found that resveratrol can have a positive impact on glucose control and insulin sensitivity.

    Amer. J Clin. Nutrition

Sign up to receive our
Press Releases!

Sign up